We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-3.23%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$4.84B
AUM Growth
-$282M
Cap. Flow
-$43.3M
Cap. Flow %
-0.89%
Top 10 Hldgs %
88.92%
Holding
82
New
22
Increased
15
Reduced
12
Closed
13

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$19.3M
2
TSLA icon
Tesla
TSLA
+$17M
3
USFD icon
US Foods
USFD
+$12.2M
4
FOLD
Amicus Therapeutics
FOLD
+$8.74M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$6.93M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$37.2M
2
MA icon
Mastercard
MA
+$18.9M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$14.2M
4
JPM icon
JPMorgan Chase
JPM
+$12.5M
5
DAL icon
Delta Air Lines
DAL
+$9.74M

Sector Composition

Rank Sector Weight
1 Consumer Staples 55.65%
2 Healthcare 23%
3 Consumer Discretionary 8.41%
4 Financials 1.55%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IBM icon
26
CALL
IBM
IBM
$213B
$15.2M 0.31%
+104,600
New +$15M
BAC icon
27
Bank of America
BAC
$429B
$14.6M 0.3%
1,100,000
+100,000
+10% +$1.4M
ARRY
28
DELISTED
Array Biopharma Inc
ARRY
$13.8M 0.28%
3,870,000
+160,000
+4% +$521K
VRTX icon
29
CALL
Vertex Pharmaceuticals
VRTX
$123B
$12.9M 0.27%
+150,000
New +$13M
USFD icon
30
US Foods
USFD
$22.5B
$12.1M 0.25%
+500,000
New +$12.2M
C icon
31
Citigroup
C
$213B
$10.6M 0.22%
250,000
– –
MS icon
32
Morgan Stanley
MS
$319B
$10.4M 0.21%
400,000
-100,000
-20% -$2.62M
MET icon
33
MetLife
MET
$62.4B
$9.96M 0.21%
280,500
+16,830
+6% +$656K
MCRB icon
34
Seres Therapeutics
MCRB
$45M
$9.01M 0.19%
15,500
+4,250
+38% +$2.49M
JUNO
35
DELISTED
Juno Therapeutics, Inc.
JUNO
$7.69M 0.16%
200,000
-65,000
-25% -$2.7M
FOLD
36
DELISTED
Amicus Therapeutics
FOLD
$6.83M 0.14%
+1,250,000
New +$8.74M
SPNC
37
DELISTED
Spectranetics Corp
SPNC
$6.55M 0.14%
350,000
– –
AVXS
38
DELISTED
AveXis, Inc. Common Stock
AVXS
$6.16M 0.13%
161,900
-13,100
-7% -$443K
HZNP
39
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$5.76M 0.12%
+350,000
New +$5.66M
CLLS
40
Cellectis
CLLS
$288M
$5.58M 0.12%
210,000
– –
JD icon
41
CALL
JD.com
JD
$43.5B
$5.31M 0.11%
+250,000
New +$6.04M
NTLA icon
42
Intellia Therapeutics
NTLA
$1.51B
$4.8M 0.1%
+225,000
New +$5.99M
BLUE
43
CALL
DELISTED
bluebird bio
BLUE
$4.33M 0.09%
+7,720
New +$4.37M
NBIX icon
44
Neurocrine Biosciences
NBIX
$18.2B
$4.32M 0.09%
+95,000
New +$4.37M
RXDX
45
DELISTED
Ignyta, Inc.
RXDX
$4.07M 0.08%
750,000
+250,000
+50% +$1.66M
AGEN
46
Agenus
AGEN
$276M
$4.05M 0.08%
50,950
+12,738
+33% +$993K
CCXI
47
DELISTED
ChemoCentryx, Inc.
CCXI
$4.04M 0.08%
900,000
– –
RDUS
48
CALL
DELISTED
Radius Health, Inc.
RDUS
$3.67M 0.08%
+100,000
New +$3.53M
RDUS
49
DELISTED
Radius Health, Inc.
RDUS
$3.67M 0.08%
+100,000
New +$3.53M
RARE icon
50
Ultragenyx Pharmaceutical
RARE
$2.46B
$3.67M 0.08%
+75,000
New +$4.85M
1
2
3 4

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q2 2016 Portfolio in Review

As of Q2 2016, Artal Group held 82 positions worth $4.84B, down 5.5% from $5.13B the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Artal Group's Q2 2016 filing shows 22 new, 15 increased, 12 reduced and 13 closed positions. Its largest new stake was Regeneron Pharmaceuticals: 50,000 shares worth $17.5M. The largest sale was Celgene Corp, an estimated $37.2M.

By sector, the portfolio is most concentrated in Consumer Staples at 56% of assets, down from 58% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • Artal Group's largest Q2 2016 buy was Regeneron Pharmaceuticals: 50,000 shares worth $17.5M.
  • Artal Group added most to Alnylam Pharmaceuticals in Q2 2016, an estimated $6.93M increase.
  • Artal Group's biggest Q2 2016 reduction was Nektar Therapeutics, cutting an estimated $8.94M.
  • Artal Group fully exited Celgene Corp in Q2 2016, selling an estimated $37.2M.
  • Artal Group's ten largest holdings make up 89% of its $4.84B portfolio in Q2 2016.
  • Artal Group opened 22 new positions and closed 13 in Q2 2016.
  • Artal Group's portfolio value fell 5.5% quarter-over-quarter to $4.84B.

Based on Artal Group's 13F filing for Q2 2016, filed 11 Aug 2016.